50606-58-1|1-Benzylpiperidin-3-one hydrochloride| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 50606-58-1 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 50606-58-1 ]

CAS No. :	50606-58-1
Formula :	C₁₂H₁₆ClNO
M.W :	225.71
SMILES Code :	O=C1CN(CC2=CC=CC=C2)CCC1.[H]Cl
MDL No. :	MFCD00012791
InChI Key :	OVWSFXNSJDMRPV-UHFFFAOYSA-N
Pubchem ID :	3084924

Safety of [ 50606-58-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 50606-58-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	6
Fraction Csp3	0.42
Num. rotatable bonds	2
Num. H-bond acceptors	2.0
Num. H-bond donors	0.0
Molar Refractivity	67.3
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	20.31 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.47
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.12
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.93
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.59
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.82

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.96
Solubility	0.248 mg/ml ; 0.0011 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.54
Solubility	0.65 mg/ml ; 0.00288 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.42
Solubility	0.0864 mg/ml ; 0.000383 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.92 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.24

Application In Synthesis of [ 50606-58-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 50606-58-1 ]

[ 50606-58-1 ] Synthesis Path-Downstream 1~35

1
[ 52-89-1 ]
[ 50606-58-1 ]
(5R)-7-benzyl-(5rC⁶)-1-thia-4,7-diaza-spiro[4.5]decane-3c-carboxylic acid [ No CAS ]

References: [1]Polish Journal of Chemistry,1978,vol. 52,p. 385 - 388.

2
[ 50606-58-1 ]
[ 541-41-3 ]
[ 61995-19-5 ]

References: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 1528 - 1531.

3
[ 50606-58-1 ]
[ 107-21-1 ]
[ 127364-04-9 ]

References: [1]Journal of Organic Chemistry,1991,vol. 56,p. 2386 - 2390.

4
[ 50606-58-1 ]
[ 501-53-1 ]
[ 61995-20-8 ]

References: [1]European Journal of Medicinal Chemistry,1991,vol. 26,p. 625 - 631.

5
[ 151-50-8 ]
[ 50606-58-1 ]
[ 62-53-3 ]
[ 88258-82-6 ]

References: [1]Polish Journal of Chemistry,1982,vol. 56,p. 811 - 813.

6
[ 50606-58-1 ]
[ 14813-01-5 ]

References: [1]Journal of Chemical Research, Miniprint,1983,p. 2326 - 2342.

8
[ 50606-58-1 ]
[ 120-20-7 ]
[ 204979-27-1 ]

References: [1]Synthetic Communications,2001,vol. 31,p. 401 - 408.

9
[ 50606-58-1 ]
[ 22483-09-6 ]
[ 204979-42-0 ]

References: [1]Synthetic Communications,2001,vol. 31,p. 401 - 408.

10
[ 948-65-2 ]
[ 50606-58-1 ]
[ 244086-73-5 ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 1603 - 1614.

11
[ 50606-58-1 ]
[ 782-17-2 ]
3-(1-benzyl-piperidin-3-yl)-2-(4-fluoro-phenyl)-1H-indole [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 1603 - 1614.

12
[ 50606-58-1 ]
[ 50717-82-3 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;palladium 10% on activated carbon; In methanol; under 2844.39 Torr; for 16h;	To a stirred solution of N-benzyl-3-piperidone hydrochloride hydrate (4.2 g, 18.6 mmol) and 10% palladium on carbon (0.8 g) in degassed methanol (200 mL) was added hydrogen gas to 55 psi. The reaction mixture was stirred for 16 hr and then filtered through a pad of celite. The celite was washed with methanol (200 mL). The filtrates were combined and concentrated in vacuo to a colorless oil. The oil was dissolved in tetrahydrofuran (200 mL) and then treated with di-t-butyl-dicarbonate (5.27 g, 24.1 mmol) and a saturated aqueous sodium bicarbonate solution (50 mL). The reaction was stirred for 4 hr and then concentrated in vacuo to a white solid. The solid was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was separated, washed with 1N sodium hydroxide and brine, dried over Na2SO4, and evaporated in vacuo to a colorless oil. The oil was purified by flash chromatography (silica gel, hexane:ethyl acetate 3:1) to yield 2.93 g of a colorless oil. 1H NMR (300 MHz, CDCl3) delta 3.99 (s, 2H), 3.58 (t, J=6, 2H), 2.46 (t, J=6, 2H), 1.97 (p, J=6, 2H), 1.45 (s, 9H).

References: [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 2194 - 2211.
[2]Patent: US2005/197373,2005,A1 .Location in patent: Page/Page column 23.

13
[ 50606-58-1 ]
[ 79-22-1 ]
[ 61995-18-4 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In chloroform; at 0 - 20℃; for 1h;	EXAMPLE 3; Step 1: To 1-benzyl-3-piperidone HCl salt hydrate (1 eq, 0.111 mol, 25 g) completely dissolved in chloroform (100 mL) and triethylamine (1.1 eq, 0.122 mol, 17 mL) was added methyl chloroformate (1.1 eq, 0.122 mol, 9.4 mL) dropwise at 0 C. After the dropwise addition was complete, additional methyl chloroformate (0.7 eq, 0.078 mol, 6 mL) was added, the reaction mixture warmed to room temperature, and stirred 1 h. The volatiles were removed in vacuo and the resulting residue was taken up in 1N HCl (100 mL) and washed with hexanes (3×70 mL). The aqueous layer was then extracted with ethyl acetate (3×100 mL), the combined ethyl acetate layers washed with brine (1×50 mL), dried (Na2SO4), and concentrated in vacuo to give 23 as an orange oil (10 g), which was used without further purification. Note: If the aqueous layer retains some product, it can be completely extracted using 10% isopropyl alcohol in chloroform.

References: [1]Patent: US2008/4287,2008,A1 .Location in patent: Page/Page column 64.

14
[ 271-63-6 ]
[ 50606-58-1 ]
1-benzyl-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-3-ol [ No CAS ]